DeepMed Research

Novartis AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public, Private

Established: 1996-01-01

Employees: 76K

Market Cap: $242.6B

Website: https://www.novartis.com/our-science/novartis-institutes-biomedical-research

Introduction: Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.

Clinical Trials

Evaluation of Efficacy and Safety of Tablets of Paracetamol, Dimethindene Maleate and Phenylephrine Hydrochloride in Reducing Symptoms of Common Cold and Flu

Phase 3

Completed

Conditions: Nasal Congestion
Rhinorrhea
Sneezing
Upper Respiratory Tract Infection

Interventions: Drug: Paracetamol (500 mg)/dimethindene maleate (1 mg)/ phenylephrine hydrochloride (10 mg) tablets
Drug: Paracetamol (500 mg) tablets

First Posted Date: 2011-10-07

Last Posted Date: 2017-03-03

Lead Sponsor: Novartis

Target Recruit Count: 341

Registration Number: NCT01448057

Locations: 🇧🇷
Santa Casa De Misericordia De Belo Horizonte - Avenida Francisco Sales 1111, Santa Efigenia, Belo Horizonte/MG, Brazil
🇧🇷
Sociedade Campineira De Educacao E Instrucao - Rodovia Dom Pedro I, KM 136 Parque das Universidades, Campinas/SP, Brazil
🇧🇷
Instituto de Ensino e Pesquisa Clínica do Ceará, Rua Coronel Jucá, 1952 - Dionísio Torres -, Fortaleza/CE, Brazil

and more 3 locations

Immune Response Induced by a Vaccine Against Group B Streptococcus and Safety in Pregnant Women and Their Offsprings

Phase 2

Completed

Conditions: Bacterial Infection
Gram-positive Bacterial Infection
Streptococcal Infection

Interventions: Biological: Group B Streptococcus Trivalent Vaccine
Biological: Placebo

First Posted Date: 2011-10-05

Last Posted Date: 2014-09-08

Lead Sponsor: Novartis

Target Recruit Count: 86

Registration Number: NCT01446289

Locations: 🇧🇪
UZ Leuven, Herestraat, Leuven, Belgium
🇨🇦
University of British Columbia, Rm B3 25 B, 4500 Oak Street,, Vancouver, British Columbia, Canada
🇧🇪
Regionaal Ziekenhuis Heilig Hart,, Gasthuismolenstraat 31, Tienen, Belgium

and more 2 locations

Extension Study of H01_04TP to Evaluate the Booster Response Induced by Vi-CRM197 in Adults

Phase 2

Completed

Conditions: Typhoid Fever

Interventions: Biological: NVGH Vi-CRM197

First Posted Date: 2011-09-22

Last Posted Date: 2014-03-24

Lead Sponsor: Novartis

Target Recruit Count: 51

Registration Number: NCT01438996

Locations: 🇧🇪
Centre for the Evaluation of Vaccination (CEV), Antwerp, Wilrijk, Belgium

Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Children, Older Infants and Infants

Phase 2

Completed

Conditions: Typhoid Fever

Interventions: Biological: Vi-CRM197 vaccine
Biological: Pneumococcal conjugate vaccine
Biological: Vi Polysaccharide (PS) vaccine

First Posted Date: 2011-09-20

Last Posted Date: 2014-04-10

Lead Sponsor: Novartis

Target Recruit Count: 120

Registration Number: NCT01437267

Locations: 🇵🇭
Research Institute for Tropical Medicine (RITM), Alabang, Muntinlupa City, Philippines

Evaluating the Comparative Safety and Immunogenicity of Three Lots of Novartis Meningococcal C Conjugate Vaccine in Healthy Toddlers

Phase 2

Completed

Conditions: Meningococcal Disease
Meningococcal Meningitis

Interventions: Biological: MenC-CRM ROS
Biological: MenC-CRM EMV
Biological: MenC-CRM LIQ

First Posted Date: 2011-09-15

Last Posted Date: 2017-04-25

Lead Sponsor: Novartis

Target Recruit Count: 992

Registration Number: NCT01434680

Locations: 🇵🇱
Specjalistyczny Zespol, Ul Krysiewicza, Poznan, Poland
🇵🇱
Samodzielny Zespol Publicznych Zakladow Opieki Zdrowotnej w, Ul Prusicka 5355, Trzebnica, Poland
🇵🇱
NZOZ Bioscience Sp zoo, ul Czerkaska, Bydgoszcz, Poland

and more 8 locations

Efficacy and Safety of Terbinafine Film Forming Solution in Patients With Tinea Pedis

Phase 3

Completed

Conditions: Tinea Pedis

Interventions: Drug: Terbinafine
Drug: Terbinafine Placebo

First Posted Date: 2011-09-13

Last Posted Date: 2013-12-27

Lead Sponsor: Novartis

Target Recruit Count: 290

Registration Number: NCT01433107

Locations: 🇨🇳
The Second Affiliated Hospital of Sun Yat-sen University Guangzhou, Guangdong, China
🇨🇳
Chinese Academy of Medical Sciences, Jiangsu, China
🇨🇳
Beijing University Hospital N°3, Beijing, China

and more 3 locations

Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: GSK2110183
Drug: Bortezomib
Drug: Dexamethasone

First Posted Date: 2011-09-05

Last Posted Date: 2018-08-08

Lead Sponsor: Novartis

Target Recruit Count: 90

Registration Number: NCT01428492

Locations: 🇨🇳
Novartis Investigative Site, Taipei, Taiwan

A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in Adolescents

Phase 4

Completed

Conditions: Meningococcal Meningitis

Interventions: Biological: Placebo + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine
Biological: MenACWY-CRM Conjugate Vaccine + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine

First Posted Date: 2011-08-29

Last Posted Date: 2014-02-14

Lead Sponsor: Novartis

Target Recruit Count: 801

Registration Number: NCT01424644

Locations: 🇺🇸
Prairie Fields Family Medicine, 350 W. 23rd Street, Suite A, Fremont, California, United States
🇮🇹
HOSPITAL"SAN MARTINO". Department of Health Sciences University of Genoa, Via Pastore, 1, Genoa, Italy
🇺🇸
Clinical Research Advantage / Colorado Springs Health Partners, 6340 Barnes Road, Colorado Springs, Colorado, United States

and more 17 locations

Safety and Immunogenicity of Novartis Meningococcal B Vaccine Formulated With OMV Manufactured at Two Different Sites, in Healthy Adolescents Aged 11-17 Years

Phase 3

Completed

Conditions: Meningococcal Disease
Meningococcal Meningitis

Interventions: Biological: Serogroup B meningococcal vaccine

First Posted Date: 2011-08-25

Last Posted Date: 2015-02-20

Lead Sponsor: Novartis

Target Recruit Count: 344

Registration Number: NCT01423084

Locations: 🇦🇺
Telethon Institute for Child Heath Research-cnr, Hamilton Street and Roberts Road-Subiaco, Western Australia, Australia
🇦🇺
AusTrials Pty Ltd-Suites 6, 10 & 11, Peninsula Specialist Centre, Kippa-Ring, Queensland, Australia
🇨🇦
SKDS Research Inc, 221-679 Davis Dr.Newmarket, Toronto, Ontario, Canada

and more 10 locations

Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Subjects From 2 to 18 Years in Taiwan

Phase 3

Completed

Conditions: Bacterial Meningitis

Interventions: Biological: Meningococcal ACWY conjugate vaccine

First Posted Date: 2011-08-05

Last Posted Date: 2014-09-22

Lead Sponsor: Novartis

Target Recruit Count: 341

Registration Number: NCT01410474

Locations: 🇨🇳
Mackay Memorial Hospital,, Taipei, Taiwan, China
🇨🇳
Far Eastern Memorial Hospital,, Taipei, Taiwan, China
🇨🇳
National Taiwan University Hospital, Taipei, Taiwan, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy